Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4D Molecular Therapeutics ( (FDMT) ) has issued an update.
On June 17, 2025, 4D Molecular Therapeutics held its Annual Meeting of Stockholders virtually, where 38,470,536 shares were voted on four proposals. The stockholders elected Class II directors, ratified the selection of PricewaterhouseCoopers LLP as the independent auditor, approved executive compensation, and decided to hold annual advisory votes on executive compensation.
The most recent analyst rating on (FDMT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
4D Molecular Therapeutics faces considerable financial and valuation challenges, reflected in its negative P/E ratio and cash flow issues. While technical indicators show short-term bullish momentum, the stock is overbought, suggesting a potential correction. The company’s future hinges on successful research outcomes and maintaining external financing.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of gene therapy products. The company is engaged in creating transformative therapies for patients with serious genetic diseases.
Average Trading Volume: 591,622
Technical Sentiment Signal: Sell
Current Market Cap: $189.5M
See more data about FDMT stock on TipRanks’ Stock Analysis page.